# HuHuangLianzonggan Capsule in Subjects With Nonalcoholic Steatohepatitis: a Phase 2 tRial(HHL-HEPAR)

> **NCT05632861** · PHASE2 · RECRUITING · sponsor: **Tasly Pharmaceutical Group Co., Ltd** · enrollment: 76 (estimated)

## Conditions studied

- NASH

## Interventions

- **DRUG:** HuHuangLianzonggan capsule
- **DRUG:** HuHuangLianzonggan capsule placebo

## Key facts

- **NCT ID:** NCT05632861
- **Lead sponsor:** Tasly Pharmaceutical Group Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-21
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2024-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05632861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05632861, "HuHuangLianzonggan Capsule in Subjects With Nonalcoholic Steatohepatitis: a Phase 2 tRial(HHL-HEPAR)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05632861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*